Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

Buchler, Tomas; Pavlik, Tomas; Melichar, Bohuslav; Bortlicek, Zbynek; Usiakova, Zuzana; Dusek, Ladislav; Kiss, Igor; Kohoutek, Milan; Benesova, Vera; Vyzula, Rostislav; Abrahamova, Jitka; Obermannova, Radka

doi:10.1186/1471-2407-14-323

BMC Cancer

Article metrics
Last updated: Sun, 5 May 2024 6:38:23 Z

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

Access & Citations

3807

Article Accesses
16

Web of Science
14

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com